JHVEPhoto BeiGene (NASDAQ:BGNE) has obtained FDA Fast Track Designation for its investigational cancer therapy. BGB-16673, an orally obtainable BTK-targeting chimeric degradation activation compound, gained fast track…
JHVEPhoto BeiGene (NASDAQ:BGNE) has acquired FDA Fast Track Designation for its investigational cancer therapy. BGB-16673, an orally accessible BTK-targeting chimeric degradation activation compound, gained fast track…
